Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 10/20 | 0.47 |
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 3/20 | 0.35 |
| ▸ | LSS | P48449 | 1/20 | 0.33 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22397637 | 0.86 | ROCK1 (0.47) | ROCK1MAP3K14CYP17A1IDO1LSS | |
| SCHEMBL23494403 | 0.83 | GPR6 (0.36) | ROCK1MAP3K14CYP17A1IDO1CDC7 | |
| SCHEMBL22397667 | 0.83 | ROCK1 (0.45) | ROCK1CYP17A1IDO1 | |
| SCHEMBL22397733 | 0.81 | IDO1 (0.42) | ROCK1CYP17A1IDO1 | |
| SCHEMBL22397668 | 0.71 | IDO1 (0.54) | IDO1 | |
| SCHEMBL15831245 | 0.64 | ROCK1 (1.00) | ROCK1MAP3K14SRD5A1CDC7CDK2 | |
| Hydrochloric Acid SCHEMBL12813094 | 0.63 | ROCK1 (0.97) | ROCK1MAP3K14SRD5A1CDC7CDK2 | |
| SCHEMBL24138155 | 0.60 | IDO1 (0.42) | ROCK1MAP3K14CYP17A1IDO1CDC7 | |
| SCHEMBL22397523 | 0.59 | IDO1 (0.48) | ROCK1MAP3K14CYP17A1IDO1 | |
| SCHEMBL30655823 | 0.59 | PNMT (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3703692-B1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-12275729-B2 | Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | MERCK SHARP & DOHME LLC (US) | 2025-04-15 | — | — | US | disclosed |
| US-20210179607-A1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3703692-A1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2020-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210179607-A1 | NOVEL SUBSTITUTED TETRAHYDROQUINOLIN COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE (IDO) INHIBITORS | IDO1, IDO2, KYNU | ROCK1 1453/4885MAP3K14 2755/4885CYP17A1 452/4885 |
| US-12275729-B2 | Substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors | IDO1, IDO2, INMT | ROCK1 1277/4885MAP3K14 2489/4885CYP17A1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.